Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Zanubrutinib Shows Superior PFS vs Venetoclax/Obinutuzumab in Indirect Comparison of Treatment-Naive CLL

September 25th 2025

An indirect comparison of SEQUOIA and CLL14 shows zanubrutinib improved PFS over venetoclax/obinutuzumab in treatment-naive CLL after baseline adjustment.

Dr Ghia on Safety Considerations After Fixed-Duration Ibrutinib Plus Venetoclax in CLL

September 18th 2025

Paolo Ghia, MD, PhD, discusses the safety considerations of fixed-duration ibrutinib plus venetoclax after retreatment in patients with CLL.

Final CAPTIVATE Analysis Data Support Frontline Fixed-Duration Ibrutinib Plus Venetoclax in CLL/SLL

September 16th 2025

Paolo Ghia, MD, PhD, details the final analysis of the phase 2 CAPTIVATE study evaluating frontline ibrutinib/venetoclax in patients with CLL.

Dr Dorritie on the Use of Pirtobrutinib Following Prior BTK Inhibition in CLL

September 15th 2025

Kathleen A. Dorritie, MD, discusses data that inform the use of pirtobrutinib and liso-cel for the treatment of patients with chronic lymphocytic leukemia.

The OncFive: Top Oncology Articles for the Week of 9/7

September 13th 2025

The FDA has approved TAR-200 in urothelial cancer and selumetinib in pediatric NF-1–associated inoperable plexiform neurofibromas, and more.

Bexobrutideg Shows Early Promise in BTK- and BCL2-Exposed, Relapsed/Refractory CLL

September 12th 2025

The novel BTK degrader led to fast-onset responses that were maintained over time in patients with CLL/SLL.

Pirtobrutinib Monotherapy Meets Primary PFS End Point in Treatment-Naive CLL/SLL

September 8th 2025

Topline results from the BRUIN CLL-313 study show a significant improvement in PFS with pirtobrutinib vs chemoimmunotherapy in treatment-naive CLL/SLL.

Dr Shadman on the Impetus for Assessing Zanubrutinib Plus Venetoclax in Previously Untreated CLL/SLL

September 5th 2025

Mazyar Shadman, MD, MPH, details the rationale for investigating the combination of zanubrutinib and venetoclax in treatment-naive CLL/SLL.

Zanubrutinib Extends PFS vs Acalabrutinib Plus Venetoclax in Untreated, Low-Risk CLL

September 4th 2025

Zanubrutinib bested acalabrutinib plus venetoclax in terms of PFS in patients with treatment-naive, low-risk CLL.

Zanubrutinib Prolongs PFS, Shows Trend Toward Improved OS in MAIC Analysis in CLL

September 4th 2025

Continuous zanubrutinib improved PFS and showed a trend for improved OS vs fixed-duration venetoclax-based therapy in treatment-naive CLL/SLL.

Dr Khan on the Development of Second-Generation BTK Inhibitors in CLL

August 29th 2025

Cyrus M. Khan, MD, detailed the development of second-generation BTK inhibitors and how they compare with first-generation BTK inhibitors in CLL.

Navigating Fixed-Duration vs Continuous Therapy Requires Strategic Sequencing in CLL

August 28th 2025

In an OncLive® Peer Exchange, 4 panelists discuss navigating fixed-duration vs continuous therapy in CLL.

Dr Dorritie on the Management of Untreated and Relapsed/Refractory CLL

August 25th 2025

Kathleen A. Dorritie, MD, details the difference in care between the management of untreated CLL and relapsed/refractory CLL.

Real-World Data Highlight Feasibility of Venetoclax Plus Obinutuzumab In First-Line CLL With Comorbidities

August 22nd 2025

Venetoclax plus obinutuzumab generated safe and efficacious real-world outcomes in first-line CLL with comorbidities.

European Commission Approves Zanubrutinib Tablet Formulation for All Indications in B-Cell Malignancies

August 21st 2025

The European approval of a zanubrutinb tablet formulation covers indications in CLL, Waldenström macroglobulinemia, MZL, and follicular lymphoma.

Dr Scarfò on Early Safety Data With BGB-16673 in R/R CLL/SLL

August 15th 2025

Lydia Scarfò, MD, discusses early safety findings with the BTK degrader BGB-16673 in R/R CLL/SLL

Dr Visentin on the Effects of Sequencing on Treatment Cost in CLL

August 14th 2025

Andrea Visentin, MD, discusses data from an Italian cost analysis of treatment sequencing in CLL.

Expansion of BTK and BCL2 Inhibitors in CLL Requires Close Attention to Safety, Sequencing Considerations

August 12th 2025

Andrew Kuykendall, MD, discusses the evolving role of BTK inhibitors, as well as emerging targets and treatment modalities targeting BTK and BCL2 in CLL.

Dr Ghia on the Rationale for Evaluating Pirtobrutinib in Relapsed/Refractory CLL

August 11th 2025

Paolo Ghia, MD, highlights the rationale for evaluating pirtobrutinib for the treatment of patients with relapsed/refractory CLL.

From BTK Inhibitors to CAR T-Cell Therapies: Hematologic Malignancies Landscape Sees an ‘Explosion of New Therapies’

August 7th 2025

Kathleen A. Dorritie, MD, highlights important NCCN guideline updates and research to watch in hematologic malignancies.